Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05204147 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05204147 · ClinicalTrials.gov record · last posted 2026-08-26

Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers

Name: Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers — clinical trial record (NCT05204147)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorCity of Hope Medical Center

Started2022-06-02

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This phase I study tests the safety, side effects, and best dose of Ac225-DOTA-M5A in treating patients with CEA positive colorectal cancer that has spread to other places in the body (advanced). Ac225-DOTA-M5A is a humanized monoclonal anti-CEA antibody, linked to a radioactive agent called actinium 225. M5A attaches to CEA positive cancer cells in a targeted way and delivers actinium 225 to kill them.

Protocol amendment history 2 changes detected by DataLookout

2026-08-27

Primary completion pushed: 2026-07-21 → 2027-09-10

2026-08-27

Completion pushed: 2026-07-21 → 2027-09-10

Trial Details

NCT Number	NCT05204147
Lead Sponsor	City of Hope Medical Center Collaborators: National Cancer Institute (NCI)
Conditions	Advanced Cancer, Metastatic Cancer
Enrollment	20 participants
Start Date	2022-06-02
Primary Completion	2027-09-10 (estimated)
Study Completion	2027-09-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-26